Cardiac Biomarkers: Troponin Trends, BNP Pitfalls, and the Chronic Elevation Problem
High-sensitivity troponin changed everything. BNP is falsely low in obesity. And a single troponin is almost never enough.
Troponin: The Myocardial Injury Marker
High-Sensitivity Troponin (hs-cTn)
High-sensitivity troponin assays detect far lower concentrations than older assays, enabling faster rule-out of MI but also detecting chronic low-level myocardial injury that was previously invisible. This has created a new problem: chronic troponin elevation without acute MI.
A single troponin value is not diagnostic. Acute MI shows a rise-and-fall pattern—troponin increases >20% from baseline over 3–6 hours. Chronic elevations (stable, flat values on serial testing) indicate non-ACS myocardial stress. Always order serial troponins at 0 and 3 hours (some protocols use 0 and 1 hour for rapid rule-out with hs-cTn). A flat troponin at two time points effectively rules out acute MI.
Non-ACS Causes of Elevated Troponin
- CKD/ESRD: Chronic low-level elevation from reduced clearance + subclinical ischemia. Present in up to 75% of dialysis patients.
- Heart failure: Myocardial wall stress causes chronic troponin leak.
- Pulmonary embolism: Right ventricular strain elevates troponin (prognostic, not diagnostic for PE).
- Sepsis: Demand ischemia and direct myocardial depression.
- Myocarditis: Often dramatic elevation without coronary obstruction.
- Tachyarrhythmias: Sustained rapid rates cause supply-demand mismatch.
- Takotsubo (stress) cardiomyopathy.
- Cardiac contusion, cardioversion, ablation.
- Extreme exercise: Marathon runners commonly have mildly elevated troponin post-race (resolves in 24–48 hours).
BNP and NT-proBNP: Heart Failure Markers
B-type natriuretic peptide (BNP) and its inactive fragment NT-proBNP are released by cardiomyocytes in response to volume overload and wall stress. They are used for diagnosis and monitoring of heart failure.
| Marker | Heart Failure Unlikely | Gray Zone | Heart Failure Likely |
|---|---|---|---|
| BNP | <100 pg/mL | 100–400 | >400 |
| NT-proBNP | <300 pg/mL | 300–age-adjusted threshold | >450 (age <50), >900 (50–75), >1800 (age >75) |
The Pitfalls
Adipose tissue expresses natriuretic peptide clearance receptors, causing BNP and NT-proBNP to be falsely low in obese patients. A BMI >35 patient with dyspnea and a BNP of 80 may actually have decompensated heart failure. Use lower thresholds in obese patients (some guidelines suggest halving the cutoff).
- NT-proBNP is renally cleared: Levels are elevated in CKD/ESRD independent of volume status. BNP is less affected by renal function.
- NT-proBNP increases with age: Use age-adjusted thresholds (see table above).
- Atrial fibrillation elevates both BNP and NT-proBNP independent of heart failure.
- Sacubitril/valsartan (Entresto) inhibits BNP degradation, falsely elevating BNP. Monitor with NT-proBNP instead in patients on this medication.
- Both markers are elevated in PE (right heart strain), sepsis, and severe pneumonia—don't assume heart failure without echocardiographic correlation.
Bottom Line
Troponin is a myocardial injury marker, not an MI-specific marker. The trend (rise-and-fall vs. flat) distinguishes acute MI from chronic elevation. BNP/NT-proBNP diagnose and monitor heart failure but are falsely low in obesity and falsely high in CKD, AF, and PE. Always correlate with the clinical picture and use serial measurements.
Stay sharp out there.
